Application of compound in preparation of drug for treating type 2 diabetic cardiomyopathy
A technology for type 2 diabetes and a compound is applied in the application field of the compound in the preparation of a drug for the treatment of type 2 diabetic cardiomyopathy, and can solve the problems of lack of specific drugs, therapeutic targets, side effects and the like
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0028] Example 1 Effect test of the compound (iCRT14) of the present invention in the treatment of type 2 diabetic cardiomyopathy 1. Experimental method
[0029] 1. Construction of animal models of type 2 diabetes
[0030]Select 3-4 week-old C57BL / 6J male mice as the test subjects, after 2 weeks of high-fat diet, intraperitoneally inject STZ (85mg / kg), inject once every other day, fast for 12h before intraperitoneal injection, and avoid light The injection was completed within 30 minutes, and the animal model of type 2 diabetes was constructed, followed by high-fat feeding. The random blood glucose of mice ≥ 16.7mmol / L can be used as a model group for experiments. Mice of the same age and sex are the normal control group (Control group, CON) , mice in the normal control group had normal diet and free access to water.
[0031] 2. Main solution configuration
[0032] (1) iCRT14 suspension injection: Weigh the injection dose, add 20% PEG300 and 80% PBS solution, and mix on a vo...
Embodiment 2
[0099] Embodiment 2 Compound (iCRT14) described in the present invention pharmacokinetic detection test in mice
[0100] At present, the data on the pharmacokinetics of iCRT14 is extremely limited. We established and verified a sensitive and highly selective method to detect the concentration of iCRT14 in mouse plasma for the study of iCRT14 pharmacokinetics.
[0101] In this example, the analyte was protein precipitated with methanol. The LC-ESIMS / MS method uses an Agilent Eclipse Plus C18 column (2.1 mm×50 mm, 1.8 μm), and the mobile phase is methanol-water (containing 0.1% formic acid). The linear range is 2.5~2000ng / mL. This method was used to study the pharmacokinetic characteristics of iCRT14 after intravenous and intraperitoneal administration in mice.
[0102] experimental method:
[0103] 1. 24 C57BL / 6J mice aged 7-8 weeks were randomly divided into two groups: intravenous injection group (Iv) and intraperitoneal injection group (Ip). The injection solution is dis...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com